



10 July 2020

OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")

Result of General Meeting

Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance testing, announces, further to the announcement of 19 June 2020, the passing of the Resolutions at the General Meeting held earlier today. The Placing, Subscription and Open Offer remain conditional on Admission of the New Ordinary Shares to AIM which is expected to take place at 8.00 a.m. Monday 13 July 2020.

Voting details

The vote for Resolution 1 was carried out as a poll on the basis of proxies received and the votes of those present (45,789,393 for and 167,575 against, with 54,677 votes withheld), and on the basis of such poll it was resolved that Resolution 1 as contained in the Notice be passed as an Ordinary Resolution.

The vote for Resolution 2 was carried out as a poll on the basis of proxies received and the votes of those present (45,789,393 for and 167,575 against, with 54,677 votes withheld), and on the basis of such poll it was resolved that Resolution 2 as contained in the Notice be passed as a Special Resolution.

Total Voting Rights

With effect from Admission the Company will have 178,153,110 Ordinary Shares in issue, with no shares held in treasury. Shareholders may use this figure as the denominator by which they are required to notify their interest in, or change to their interest in, the Company under the Disclosure Guidance and Transparency Rules.

Capitalised terms not otherwise defined in the text of this announcement have the meanings given to them in the Company's circular dated 19 June 2020.

For further information, please contact:

Omega Diagnostics Group PLC

Colin King, Chief Executive

Kieron Harbinson, Group Finance Director

Tel: 01259 763 030

www.omegadiagnostics.com

finnCap Ltd

Geoff Nash / Hannah Boros / Teddy Whiley (Corporate Finance)

Camille Gochez (ECM)

Tel: 020 7220 0500

Walbrook PR Limited

Paul McManus

Lianne Cawthorne

Tel: 020 7933 8780
or omega@walbrookpr.com

Mob: 07980 541 893

Mob: 07584 391 303

Accordingly, the Company makes the following announcement and notification in accordance with the EU Market Abuse Regulation (No 596/2014):

1.	Details of Persons Discharging Managerial Responsibilities "PD MR" / person closely associated with them ('PCA')					
a)	Name	Colin King				
2.	Reason for notification					
b)	Position / status	CEO				
c)	Initial notification / amendment	Initial Notification				
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
b)	Name	Omega Diagnostics Group plc				
c)	LEI	2138007U9P4BTZTYIR92				
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a)	Description of the financial instrument	ordinary shares of 4p each				
	Identification code	GB00B1VCP282				
b)	Nature of the transaction	Acquisition of shares pursuant to the Placing				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>£0.40</td> <td>50,000</td> </tr> </tbody> </table>	Price(s)	Volume(s)	£0.40	50,000
Price(s)	Volume(s)					
£0.40	50,000					
d)	Aggregated information Aggregated volume Price	n/a				
e)	Date of the transaction	13 July 2020				
f)	Place of the transaction	London Stock Exchange, AIM Market (XLON)				

1.	Details of Persons Discharging Managerial Responsibilities "PD MR" / person closely associated with them ('PCA')	
a)	Name	Kieron Harbinson
2.	Reason for notification	
b)	Position / status	CFO

c)	Initial notification / amendment	Initial Notification				
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor					
b)	Name	Omega Diagnostics Group plc				
c)	LEI	2138007U9P4BTZTYIR92				
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a)	Description of the financial instrument	ordinary shares of 4p each				
	Identification code	GB00B1VCP282				
b)	Nature of the transaction	Acquisition of shares pursuant to the Subscription and Open Offer				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>£0.40</td> <td>35,914</td> </tr> </tbody> </table>	Price(s)	Volume(s)	£0.40	35,914
Price(s)	Volume(s)					
£0.40	35,914					
d)	Aggregated information Aggregated volume Price	n/a				
e)	Date of the transaction	13 July 2020				
f)	Place of the transaction	London Stock Exchange, AIM Market (XLON)				

1.	Details of Persons Discharging Managerial Responsibilities "PDMR" / person closely associated with them ('PCA')	
a)	Name	Jag Grewal
2.	Reason for notification	
b)	Position / status	Commercial Director
c)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
b)	Name	Omega Diagnostics Group plc
c)	LEI	2138007U9P4BTZTYIR92

4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a)	Description of the financial instrument Identification code	ordinary shares of 4p each GB00B1VCP282				
b)	Nature of the transaction	Acquisition of shares pursuant to the Placing				
c)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Price(s)</th> <th>Volume(s)</th> </tr> </thead> <tbody> <tr> <td>£0.40</td> <td>22,500</td> </tr> </tbody> </table>	Price(s)	Volume(s)	£0.40	22,500
Price(s)	Volume(s)					
£0.40	22,500					
d)	Aggregated information Aggregated volume Price	n/a				
e)	Date of the transaction	13 July 2020				
f)	Place of the transaction	London Stock Exchange, AIM Market (XLON)				

1.	Details of Persons Discharging Managerial Responsibilities "PDMR" / person closely associated with them ('PCA')	
a)	Name	Jeremy Millard
2.	Reason for notification	
b)	Position / status	Non-Executive Director
c)	Initial notification / amendment	Initial Notification
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
b)	Name	Omega Diagnostics Group plc
c)	LEI	2138007U9P4BTZTYIR92
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument Identification code	ordinary shares of 4p each GB00B1VCP282

b)	Nature of the transaction	Acquisition of shares pursuant to the Subscription	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£0.40	25,000
d)	Aggregated information Aggregated volume Price	n/a	
e)	Date of the transaction	13 July 2020	
f)	Place of the transaction	London Stock Exchange, AIM Market (XLON)	